海角破解版

Rho Kinase Inhibitor IV

RHO/ROCK pathway inhibitor; Inhibits ROCK2

Rho Kinase Inhibitor IV

RHO/ROCK pathway inhibitor; Inhibits ROCK2

Catalog #
(Select a product)
RHO/ROCK pathway inhibitor; Inhibits ROCK2
Request Pricing Request Pricing

Overview

Rho Kinase Inhibitor IV is a selective and potent inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2; IC鈧呪個 = 11.8 nM; Tamura et al.). It is a glycyl analog of Fasudil (Catalog #73662) with increased specificity for ROCK2 (Tamura). Rho Kinase Inhibitor IV is more potent than other ROCK inhibitors, including Y-27632 (Ki = 220 nM) and Fasudil (IC鈧呪個 = 158 nM). It shows good specificity for ROCK2 compared to other kinases such as calcium/calmodulin-dependent kinase type II (IC鈧呪個 = 2.57 渭M), PKG (IC鈧呪個 = 2.35 渭M), Aurora A (IC鈧呪個 = 3.26 渭M), or PKA or PKC (IC鈧呪個 鈮 10 渭M each). ROCK1 and ROCK2 act downstream of the G protein Rho to regulate actin-myosin turnover and dynamics, and play an important role in stem cell renewal, smooth muscle contraction, cell adhesion, and proliferation (Narumiya et al.; Olson; Watanabe et al.). This product is supplied as a 5 mg/mL solution in methanol.

DIFFERENTIATION
路 Promotes neurite growth in primary rat neuronal cultures (Al-Ali et al.).
路 Impairs primitive gut tube development including midgut elongation in Xenopus embryos (Reed et al.).

DISEASE MODELING
路 Reduces intraocular pressure in a rabbit model of glaucoma (Tamura et al.).
Alternative Names
(S)-Glycyl-H-1152
Cell Type
Intestinal Cells, Neurons
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Differentiation
Area of Interest
Disease Modeling, Neuroscience, Stem Cell Biology
CAS Number
Rho Kinase Inhibitor IV: 913844-45-8, Methanol: 67-56-1
Chemical Formula
C鈧佲倛H鈧傗倓N鈧凮鈧僑 路 2HCl
Molecular Weight
449.4 g/mol
Purity
鈮 98%
Pathway
RHO/ROCK
Target
ROCK2

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
73804, 73802
Lot #
All
Language
English
Document Type
Product Name
Catalog #
73804, 73802
Lot #
All
Language
English

Resources and Publications

Publications (7)

Rapid and efficient induction of functional astrocytes from human pluripotent stem cells. I. Canals et al. Nature methods 2018 SEP

Abstract

The derivation of astrocytes from human pluripotent stem cells is currently slow and inefficient. We demonstrate that overexpression of the transcription factors SOX9 and NFIB in human pluripotent stem cells rapidly and efficiently yields homogeneous populations of induced astrocytes. In our study these cells exhibited molecular and functional properties resembling those of adult human astrocytes and were deemed suitable for disease modeling. Our method provides new possibilities for the study of human astrocytes in health and disease.
Morphogenesis of the primitive gut tube is generated by Rho/ROCK/myosin II-mediated endoderm rearrangements. Al-Ali H et al. ACS chemical biology 2013 MAY

Abstract

During digestive organogenesis, the primitive gut tube (PGT) undergoes dramatic elongation and forms a lumen lined by a single-layer of epithelium. In Xenopus, endoderm cells in the core of the PGT rearrange during gut elongation, but the morphogenetic mechanisms controlling their reorganization are undetermined. Here, we define the dynamic changes in endoderm cell shape, polarity, and tissue architecture that underlie Xenopus gut morphogenesis. Gut endoderm cells intercalate radially, between their anterior and posterior neighbors, transforming the nearly solid endoderm core into a single layer of epithelium while concomitantly eliciting radially convergent" extension within the gut walls. Inhibition of Rho/ROCK/Myosin II activity prevents endoderm rearrangements and consequently perturbs both gut elongation and digestive epithelial morphogenesis. Our results suggest that the cellular and molecular events driving tissue elongation in the PGT are mechanistically analogous to those that function during gastrulation锟
Development of specific Rho-kinase inhibitors and their clinical application. Al-Ali H et al. ACS chemical biology 2013 MAY

Abstract

Hexahydro-1-(isoquinoline-5-sulfonyl)-1H-1,4-diazepine, HA-1077, is a known selective inhibitor of Rho-kinase. Although its IC(50) value against Rho-kinase is more than 10 times lower than those for kinases such as PKA, PKB, PKC, PKG, MLCK, CaMKII and others, the molecule still retains relative potent inhibition activities against these kinases. In order to produce highly specific Rho-kinase inhibitors, several HA-1077 analogs were synthesized and their kinase inhibition properties evaluated. (S)-Hexahydro-1-(4-ethenylisoquinoline-5-sulfonyl)-2-methyl-1H-1,4-diazepine was found to be a potent Rho-kinase inhibitor. The IC50 value against Rho-kinase was 6 nM, while those against other kinases remained at almost the same level as that of HA-1077. Furthermore, we designed HA-1077 analogs on the basis of the complex structure of PKA and HA-1077. Amongst these, (S)-hexahydro-4-glycyl-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1H-1,4-diazepine and other glycine derivatives were found to be highly specific Rho-kinase inhibitors. These Rho-kinase specific inhibitors were applied to rabbit ocular hypertensive models and were shown to reduce intraocular pressure. These results demonstrate that the new 5-isoquinolinesulfonylamides are not only potent ROCK selective compounds, but are also useful compounds for clinical applications.